Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Mutiple Myeloma at the 19th Congress of the European Hematology Association: What is new?

During the meeting, recently developed approaches for diagnosis and monitoring will be presented. Gene-expression-profiling to detect molecular subgroups with a different prognosis and high-throughput-sequencing to identify new genetic lesions will be discussed.

Application forms

The deadline for the EHA Corporate Sponsor application is September 6, 2024, at 13:00 (CEST). Interested in becoming an EHA sponsor? Below you will find all the application forms for all the available EHA Sponsor Programs.

Clinical Research Training in Hematology Hall of Fame

European Board for Accreditation in Hematology

Current committee members
Harry Schouten, The Netherlands (Chair)
Anna Porwit, Sweden (Vice-Chair)
Gunnar Birgegård, Sweden, General skills and ethics
Peter van den Burg, The Netherlands, Transfusion Medicine (ISBT)
Eleni Gavriilaki, Greece (Representative clinical hematology)
Michelle Kenyon, United Kingdom, Specialized Hematology Professional (EBMT Nurses Group)
Fionnuala Ní Áinle,…

YoungEHA featured in the European Medical Journal!

As part of a series of interviews conducted at this year’s EHA congress in Amsterdam, the European Medical Journal has published their highly insightful discussions with three distinct members: Professor Shai Izraeli, Professor Barbara Bain, and YoungEHA’s very own Dr…

Myeloproliferative Neoplasms (MPN)

The aims of the SWG are furthering collaboration and sharing knowledge between centers involved in the management of MPN, a focus to develop centers and clinicians who would be willing to host visiting staff for sabbaticals or learning experiences was…